HR Execs on the Move

The Center for Health Care Services

www.chcsbc.org

 
MAKE AN APPOINTMENT Adult: 210.261.1250 Children: 210.261.3350   The Center for Health Care Services (CHCS) is proud to present our Annual Report for Fiscal Year 2018. By making Our People, Our Community, Our Priority; CHCS is changing lives, restoring...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.chcsbc.org
  • 6800, Park Ten Boulevard
    San Antonio, TX USA 78213
  • Phone: 210.261.1250

Executives

Name Title Contact Details

Similar Companies

Tanis Technical

Tanis Technical is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

FFF Enterprises Inc

FFF Enterprises Inc is a Temecula, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Triad Isotopes Inc

Triad Isotopes Inc is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Silence Therapeutics

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.

BrainStorm Cell

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.